A Phase 1/2 Study of ANV419 As Monotherapy or in Combination with Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients with Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANV 419 (Primary) ; Ipilimumab (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Skin cancer
Focus Adverse reactions; Therapeutic Use
Acronyms OMNIA-1
Sponsors Anaveon

Most Recent Events

27 Nov 2024 Status changed from recruiting to completed.
09 Feb 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Sep 2024.
06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight